BioSpace News Archive

Atrion Corporation announced its results for the fourth quarter ended December 31, 2022 and the full year 2022.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been dosed in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations.

Travere Therapeutics, Inc. announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175,000,000 of its common stock.

Theravance Biopharma, Inc. announced financial results for the fourth quarter and full year ended December 31, 2022.

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Tuesday, March 7, 2023.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on April 5, 2023, to all shareholders of record as of March 15, 2023.

SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2022.

Illumina, Inc. announced that its executives will be speaking at the following investor conference.

PDS Biotechnology Corporation announced the successful completion of a Type B meeting with the U.S. Food and Drug Administration for a combination therapy of PDS0101, PDS0301 and an FDA-approved immune checkpoint inhibitor for the treatment of recurrent/metastatic human papilloma virus -positive, ICI refractory head and neck cancer.